Literature DB >> 9432161

Persistent MR contrast enhancement of calcified neurocysticercosis lesions.

T N Sheth1, L Pillon, J Keystone, W Kucharczyk, L Pilon.   

Abstract

PURPOSE: We sought to determine whether cysticercosis lesions in the brain continue to enhance after nodular involution and complete calcification, and to investigate the clinical significance of this finding with respect to seizure recurrence after cysticidal treatment.
METHODS: Serial contrast-enhanced MR images were obtained in all patients with neurocysticercosis seen at our hospital over a 6-year period (1991-1997). From this group, all patients with nodular calcified lesions were selected for study.
RESULTS: Sixteen of 29 patients with neurocysticercosis had nodular calcified lesions. Six of these 16 had rim enhancement of nodular calcified lesions for at least 1 year after imaging evidence of complete calcification. Three of these six patients with enhancing, calcified lesions continued to experience seizures. Three of the 10 patients without enhancement also continued to have seizures.
CONCLUSION: Contrary to the literature, which states that enhancement and disease activity cease with calcification, six (38%) of 16 patients had lesions that continued to enhance after complete calcification. This abnormality may be a risk factor for posttreatment seizures or may suggest eventual resorption of the calcified lesion.

Entities:  

Mesh:

Year:  1998        PMID: 9432161      PMCID: PMC8337340     

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  21 in total

1.  Epilepsy and intracranial calcification of unknown origin.

Authors:  Ethem M Arsava; Serap Saygi
Journal:  J Neurol       Date:  2005-04-15       Impact factor: 4.849

2.  Corticosteroid withdrawal precipitates perilesional edema around calcified Taenia solium cysts.

Authors:  Rojelio Mejia; Theodore E Nash
Journal:  Am J Trop Med Hyg       Date:  2013-09-03       Impact factor: 2.345

3.  The role of conventional MR imaging sequences in the evaluation of neurocysticercosis: impact on characterization of the scolex and lesion burden.

Authors:  L T Lucato; M S Guedes; J R Sato; L A Bacheschi; L R Machado; C C Leite
Journal:  AJNR Am J Neuroradiol       Date:  2007-09       Impact factor: 3.825

Review 4.  Diagnosis and treatment of neurocysticercosis.

Authors:  Theodore E Nash; Hector H Garcia
Journal:  Nat Rev Neurol       Date:  2011-09-13       Impact factor: 42.937

5.  Short report: A calcified Taenia solium granuloma associated with recurrent perilesional edema causing refractory seizures: histopathological features.

Authors:  Winnie W Ooi; Subhashie Wijemanne; Christine B Thomas; Martha Quezado; Charles R Brown; Theodore E Nash
Journal:  Am J Trop Med Hyg       Date:  2011-09       Impact factor: 2.345

6.  Atypical clinical and imaging manifestation in neurocysticercosis.

Authors:  L Dayananda; C Kesavadas; Bejoy Thomas; R Neelima; V V Radhakrishnan
Journal:  Ann Indian Acad Neurol       Date:  2011-10       Impact factor: 1.383

7.  Exploring the complex associations over time among albendazole treatment, cyst evolution, and seizure outcomes in neurocysticercosis.

Authors:  Arturo Carpio; Mindy Chang; Hongbin Zhang; Matthew L Romo; Alex Jaramillo; W Allen Hauser; Elizabeth A Kelvin
Journal:  Epilepsia       Date:  2019-07-29       Impact factor: 5.864

8.  Perilesional brain oedema and seizure activity in patients with calcified neurocysticercosis: a prospective cohort and nested case-control study.

Authors:  Theodore E Nash; E Javier Pretell; Andres G Lescano; Javier A Bustos; Robert H Gilman; Armando E Gonzalez; Héctor H Garcia
Journal:  Lancet Neurol       Date:  2008-11-03       Impact factor: 44.182

Review 9.  Taenia solium cysticercosis.

Authors:  Héctor H García; Armando E Gonzalez; Carlton A W Evans; Robert H Gilman
Journal:  Lancet       Date:  2003-08-16       Impact factor: 79.321

10.  Diagnosis and treatment of neurocysticercosis.

Authors:  Christina M Coyle; Herbert B Tanowitz
Journal:  Interdiscip Perspect Infect Dis       Date:  2009-08-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.